The clinical features and drug resistance of 10 patients with linezolid-nonsusceptible Enterococcal blood stream infection

Hui XU,Hua ZHOU,Qing YANG,Yihong SHEN,Jianying ZHOU

DOI: https://doi.org/10.13381/j.cnki.cjm.201608014

2016-01-01

Abstract:Objective To observe the clinical features,antimicrobial therapy and outcomes of 10 patients with linezolid-nonsusceptible enterococcal bloodstream infections (BSI).Methods A retrospective analysis was performed on the clinical characteristics and drug resistance of patients with linezolid-nonsusceptible enterococcal BSI in the First affiliated Hospital,Zhejiang University from February 2013 to October 2014.Results All the 10 patients had severe concurrent basic diseases and accepted invasive operations in previous 2 weeks.6 cases accepted surgical treatments within 3 months before getting positive culture results,8 cases had antibacterial drug exposure within 2 weeks;none had linezolid exposure within 1 year.4 patients received glycopeptides therapy,4 patients received carbapenems therapy,1 patient received tigecycline and piperacillin/tazobactam combination therapy,and 1 patient received quinolone and aminoglycoside combination therapy.After treatment,there were 7 cases of bacteria removal,6 cases of clinical improvement;4 cases died of MODS.6 linezolid-resistant strains and 4 linezolid-mediated strains were detected,all of which were sensitive to vancomycin,tigecycline and teicoplanin,while resistant to most of the other antibiotics.Conclusion Linezolid-nonsusceptible Enterococcal BSI are often complicated with severe basic diseases,and the patients had a history of repeated hospitalization and antibiotic exposure.Due to multidrug-resistance,the infections of these patients are refractory,which causes high mortality among them.Appropriate antibiotic use and normative nosocomial infection control are important measures to effectively reduce the emergence of drug-resistant strains.